



Sheet 1 of 2


<p style="text-align: center;"><b>U.S. DEPARTMENT OF COMMERCE</b>  <b>PATENT AND TRADEMARK OFFICE</b></p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(Use several sheets if necessary)</p>	ATTY. DOCKET NO: 69273-0009	APPLICATION NO.: 09/758,781
	APPLICANT Elliot FARBER	
	FILING DATE January 11, 2001	GROUP: 1617 Examiner: S. Sharareh

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	CITE NO.	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	4,767,618	08/30/1988	Grollier et al.	424	74	10/22/1985
	2	4,933,177	06/12/1990	Grollier et al.	424	74	06/15/1988
	3	5,176,916	01/05/1993	Yamanaka et al.	424	448	04/17/1991
	4	5,476,664	12/19/1995	Robinson et al.	424	443	04/15/1994
	5	5,753,245	05/19/1998	Fowler et al.	424	401	02/19/1997
	6	5,871,762	02/16/1999	Venkitaraman et al.	424	402	10/07/1996
	7	6,077,520	06/20/2000	Tominaga	424	401	02/13/1998
	8	6,169,114 B1	01/02/2001	Yamaguchi et al.	514	562	05/05/1999

## **FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**


**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

FORM PTO-1449 (M dified) <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	ATTY. DOCKET NO: 69273-0009	APPLICATION NO.: 09/758,781
	<b>APPLICANT</b> Elliot FARBER	
	FILING DATE January 11, 2001	GROUP: 1617 Examiner: S. Sharareh

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initials	Cite No.	
	9	P. LeVan et al., "The Use of Silicones in Dermatology," <u>Calif. Med.</u> 81:210-213 (1954)
	10	R. Cahen & A. Pessonner, "Etude Pharmacologique de L'Allantoinate de Dihydroxyaluminium et de L' Allantoinate de Chlorhydroxyaluminium. I.—Toxicité," <u>Ann. Pharm. Franc.</u> 20:623-636 (1962) (in French), discloses the physical and chemical properties and the toxicity of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. The compounds were observed to have no toxicity.
	11	R. Cahen & J.-F. Clement, "Etude Pharmacologique de L'Allantoinate de Dihydroxyaluminium et de L' Allantoinate de Chlorhydroxyaluminium. II.—Etude de l'Activité Gastroïque," <u>Ann Pharm. Franc.</u> 20:693-703 (1962) (in French), discloses the activity of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate on gastric activity. The compounds were found to have acid-neutralizing and buffering activity and to diminish gastric acidity.
	12	R. Cahen & A. Pessonner, "Etude Pharmacologique de L'Allantoinate de Dihydroxyaluminium et de L' Allantoinate de Chlorhydroxyaluminium. III.—Effet Anti-ulcérœux," <u>Ann. Pharm. Franc.</u> 20:704-713 (1962) (in French), discloses the anti-ulcer activity of the compounds dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. The compounds were found to have anti-ulcer activity in rats and guinea pigs comparable to compounds such as aluminum hydrate and bismuth subnitrate.
	13	R. Cahen & A. Pessonner, "Etude Pharmacologique de L'Allantoinate de Dihydroxyaluminium et de L' Allantoinate de Chlorhydroxyaluminium. IV.—Effet sur l'Ulcère Médicamenteux Expérimental," <u>Ann. Pharm. Franc.</u> 21:215-222 (1963) (in French), discloses the effect of the compounds dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate on ulcers produced in the rat by administration of phenylbutazone or reserpine. The compounds were found to have activity against such ulcers.
	14	C. Debray et al., "Etude de Dérivés Allantoiniques de l'Aluminium dans la Thérapeutique des Affections Gastro-duodénales," <u>Presse Méd.</u> 70:2643-44 (1962) (in French) discloses the activity of the compounds dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate administered in a complex with a polymer of polyoxyethylene and polyoxypropanediol, methylhomatropine bromide, and calcium carbonate on gastrointestinal conditions. The complex was said to be effective against duodenal ulcer and effective in protecting the gastric mucosa.
<b>EXAMINER</b>		
	DATE CONSIDERED <u>12/11/03</u>	
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		